TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06569966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon
Description: The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
Study: NCT06571318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Destress and Perform Capsule-U001
Description: Two Capsules in sequence daily after meal for 60 days.
Study: NCT05025072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide film-coated tablet
Description: Hydroxycarbamide film-coated tablet (1000 mg)
Study: NCT06571318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Destress and Perform Capsule-I001
Description: Two Capsules in sequence daily after meal for 60 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsules 002
Description: Two Capsules in sequence daily after meal for 60 days
Study: NCT06570226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hibiscus tea
Description: Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
Study: NCT06569615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shock wave therapy
Description: All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LASER Therapy
Description: All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
Study: NCT06243224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
Study: NCT05025072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide film-coated tablet
Description: Hydroxycarbamide film-coated tablet (1000 mg)
Study: NCT06243224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training
Description: Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
Study: NCT06026410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KO-2806
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KO-2806
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KO-2806
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Oral administration
Study: NCT06143553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Polymeric Micelles for Injection
Description: Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesilate injection
Description: Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Tablets
Description: Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride for Injection
Description: Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate Injection
Description: Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (albumin-bound)
Description: Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
Study: NCT05570825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXCR1/2 Inhibitor SX-682
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05281016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be offered standard care which consists of the following:~* Clinic consultation with physician and dietician,~* pamphlets on weight management principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be offered standard care which consists of the following:~* Clinic consultation with physician and dietician,~* pamphlets on weight management principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online community LITE programme
Description: Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online community LITE programme
Description: Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support.
Study: NCT05579691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT06498505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT06443047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTS suturing system
Description: The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
Study: NCT05346952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
Description: PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
Description: PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
Study: NCT05326399

Intervention type: BEHAVIORAL
Intervention: renal biospy
Description: Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
Study: NCT06203548

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification programme
Description: All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
Study: NCT04604210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
Study: NCT04903652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: Pyrotinib p.o. 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine p.o. 40 mg once every other day
Study: NCT06097702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX-001N Part 1
Description: Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX-001N Part 2
Description: Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part 1 and 2 of the study.
Study: NCT06226259

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA supplement
Description: Oral administration of GABA supplement once daily before sleep for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration of placebo once daily before sleep for 14 days.
Study: NCT06512415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mcg Norepinephrine
Description: The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 mcg Norepinephrine
Description: The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
Study: NCT05290545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBSCs
Description: PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBSCs
Description: PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord
Description: The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMSCs
Description: BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
Study: NCT05375903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-301
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-301
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-301
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-201
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
Study: NCT05542303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort1 (3mg/kg) ZB001 of single IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB001 for injection
Description: Dose Cohort2 (10mg/kg) ZB001 of single IV injection
Study: NCT06569615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
Study: NCT05653258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: 1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines.
Study: NCT06570928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: 0,2 ml of CBD:THC (50 mg:5 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product vehicle, medium chain triglycerides (MCT)
Study: NCT05055427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Description: Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day